Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.49 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.49 |
| ▸ | HTR1A | P08908 | 1/20 | 0.48 |
| ▸ | HTR2A | P28223 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | KDR | P35968 | 4/20 | 0.47 |
| ▸ | AXL | P30530 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | EGFR | P00533 | 3/20 | 0.46 |
| ▸ | HTR4 | Q13639 | 2/20 | 0.46 |
| ▸ | AURKA | O14965 | 1/20 | 0.46 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.46 |
| ▸ | LCK | P06239 | 1/20 | 0.46 |
| ▸ | FYN | P06241 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5502433 | 0.91 | LMNA (0.55) | LMNAKDM4ETDP1CYP2D6TSHR | |
| SCHEMBL3284976 | 0.91 | LMNA (0.55) | LMNAKDM4ETDP1CYP2D6TSHR | |
| SCHEMBL3471214 | 0.90 | LMNA (0.56) | LMNAKDM4ETDP1CYP2D6TSHR | |
| SCHEMBL3711173 | 0.90 | LMNA (0.56) | LMNAKDM4ETDP1CYP2D6TSHR | |
| SCHEMBL6442660 | 0.87 | LMNA (0.51) | LMNAKDM4ETDP1CYP2D6TSHR | |
| SCHEMBL3534600 | 0.87 | LMNA (0.51) | LMNAKDM4ETDP1CYP2D6TSHR | |
| SCHEMBL14667304 | 0.85 | HTR1A (0.47) | KDM4ETDP1CYP2D6TSHRKEAP1 | |
| SCHEMBL361837 | 0.83 | KDM4E (0.58) | LMNAKDM4ETDP1CYP2D6TSHR | |
| SCHEMBL19260705 | 0.80 | HTR4 (0.56) | CYP2D6ALDH1A1HTR4MEN1CYP3A4 | |
| SCHEMBL2926517 | 0.80 | HTR4 (0.56) | CYP2D6HTR1AALDH1A1HTR4MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2768796-B1 | PROCESS FOR PREPARING QUINOLINE DERIVATIVES | EXELIXIS INC (US) | 2019-11-20 | — | — | EP | disclosed |
| EP-2768796-B1 | PROCESS FOR PREPARING QUINOLINE DERIVATIVES | EXELIXIS INC (US) | 2019-11-20 | — | — | EP | disclosed |
| US-9969692-B2 | Process for preparing quinoline derivatives | EXELIXIS, INC. (US) | 2018-05-15 | — | — | US | disclosed |
| US-9969692-B2 | Process for preparing quinoline derivatives | EXELIXIS, INC. (US) | 2018-05-15 | — | — | US | disclosed |
| US-20160229805-A1 | Process for Preparing Quinoline Derivatives | EXELIXIS, INC. | 2016-08-11 | — | — | US | disclosed |
| US-20160229805-A1 | Process for Preparing Quinoline Derivatives | EXELIXIS, INC. | 2016-08-11 | — | — | US | disclosed |
| US-9365516-B2 | Process for preparing quinoline derivatives | EXELIXIS, INC. (US) | 2016-06-14 | — | — | US | disclosed |
| US-9365516-B2 | Process for preparing quinoline derivatives | EXELIXIS, INC. (US) | 2016-06-14 | — | — | US | disclosed |
| US-20140256938-A1 | Process for Preparing Quinoline Derivatives | EXELIXIS, INC. | 2014-09-11 | — | — | US | disclosed |
| US-20140256938-A1 | Process for Preparing Quinoline Derivatives | EXELIXIS, INC. | 2014-09-11 | — | — | US | disclosed |
| US-8314232-B2 | Preparation of a quinolinyloxydiphenylcyclopropanedicarboxamide | GLAXOSMITHKLINE LLC (US) | 2012-11-20 | — | — | US | disclosed |
| US-8314232-B2 | Preparation of a quinolinyloxydiphenylcyclopropanedicarboxamide | GLAXOSMITHKLINE LLC (US) | 2012-11-20 | — | — | US | disclosed |
| WO-2012044574-A1 | DUAL INHIBITORS OF MET AND VEGF FOR THE TREATMENT OF CASTRATION RESISTANT PROSTATE CANCER AND OSTEOBLASTIC BONE METASTASES | EXELIXIS, INC. (US) | 2012-04-05 | — | — | WO | disclosed |
| WO-2012044574-A1 | DUAL INHIBITORS OF MET AND VEGF FOR THE TREATMENT OF CASTRATION RESISTANT PROSTATE CANCER AND OSTEOBLASTIC BONE METASTASES | EXELIXIS, INC. (US) | 2012-04-05 | — | — | WO | disclosed |
| WO-2012044577-A1 | DUAL INHIBITORS OF MET AND VEGF FOR THE TREATMENT OF CASTRATION RESISTANT PROSTATE CANCER AND OSTEOBLASTIC BONE METASTASES | EXELIXIS, INC. (US) | 2012-04-05 | — | — | WO | disclosed |
| WO-2012044577-A1 | DUAL INHIBITORS OF MET AND VEGF FOR THE TREATMENT OF CASTRATION RESISTANT PROSTATE CANCER AND OSTEOBLASTIC BONE METASTASES | EXELIXIS, INC. (US) | 2012-04-05 | — | — | WO | disclosed |
| WO-2012009723-A1 | C-MET MODULATOR PHARMACEUTICAL COMPOSITIONS | EXELIXIS, INC. (US) | 2012-01-19 | — | — | WO | disclosed |
| US-20100081805-A1 | Preparation of a Quinolinyloxydiphenylcyclopropanedicarboxamide | EXELIXIS, INC. | 2010-04-01 | — | — | US | disclosed |
| US-20100081805-A1 | Preparation of a Quinolinyloxydiphenylcyclopropanedicarboxamide | EXELIXIS, INC. | 2010-04-01 | — | — | US | disclosed |
| WO-2010036831-A1 | PREPARATION OF A QUINOLINYLOXYDIPHENYLCYCLOPROPANEDICARBOXAMIDE | GLAXOSMITHKLINE LLC (US) | 2010-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160229805-A1 | Process for Preparing Quinoline Derivatives | C5, C1S, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | LMNA 1100/4885KDM4E 4552/4885TDP1 2361/4885 |
| US-20140256938-A1 | Process for Preparing Quinoline Derivatives | C5, C1S, C1R | LMNA 1025/4885KDM4E 4568/4885TDP1 2413/4885 |
| US-20100081805-A1 | Preparation of a Quinolinyloxydiphenylcyclopropanedicarboxamide | QDPR, CBR3, NQO2 | LMNA 2416/4885KDM4E 1032/4885TDP1 3247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.